Listed

PharmaCyte Biotech, Inc.: Form 10-Q/A for the period ended Jan 31, 2017

Filed with the SEC on Mar 13, 2017 and accepted by EDGAR at Mar 13, 2017, 08:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-01-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-11-01 to 2017-01-31$0us-gaap:Revenues
Revenue9 months2016-05-01 to 2017-01-31$0us-gaap:Revenues
Cost of revenue3 months2016-11-01 to 2017-01-31$0us-gaap:CostOfRevenue
Cost of revenue9 months2016-05-01 to 2017-01-31$0us-gaap:CostOfRevenue
Gross profit3 months2016-11-01 to 2017-01-31$0us-gaap:GrossProfit
Gross profit9 months2016-05-01 to 2017-01-31$0us-gaap:GrossProfit
Research and development3 months2016-11-01 to 2017-01-31$579.7kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2016-05-01 to 2017-01-31$1.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-11-01 to 2017-01-31−$1.3mus-gaap:OperatingIncomeLoss
Operating income9 months2016-05-01 to 2017-01-31−$3.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-11-01 to 2017-01-31$131us-gaap:InterestExpense
Interest expense9 months2016-05-01 to 2017-01-31$1.1kus-gaap:InterestExpense
Net income3 months2016-11-01 to 2017-01-31−$1.3mus-gaap:NetIncomeLoss
Net income9 months2016-05-01 to 2017-01-31−$3.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-11-01 to 2017-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2016-05-01 to 2017-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2016-11-01 to 2017-01-31859,529,933 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2016-05-01 to 2017-01-31832,203,911 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Cash and equivalentsAt period end2017-01-31$2.5mus-gaap:Cash
Current assetsAt period end2017-01-31$2.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-01-31$7.6mus-gaap:Assets
Current liabilitiesAt period end2017-01-31$578.3kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-01-31$578.3kus-gaap:Liabilities
Shareholders' equityAt period end2017-01-31$7.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-17-000544. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.